QualityStocksNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Draws ‘Buy’ Rating on Lucid-MS Potential
Disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising. Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) received a ‘Buy’ rating from Rodman & Renshaw, which initiated coverage with an $8.00 price target based on the company’s Lucid-MS drug candidate. Described as a potentially first-in-class non-immunomodulatory small molecule, Lucid-MS is being developed to address neurodegeneration and disability progression in progressive multiple sclerosis, an area where therapeutic options remain limited. The firm’s $8.00 price target reflects its valuation of Quantum BioPharma’s development pipeline. For more information on Lucid-MS, visit https://ibn.fm/8uqwL About Quantum BioPharma Ltd. Quantum is a biopharmaceutical company dedicated to building a…